Alimera Sciences Inc (NASDAQ:ALIM)

4.55
Delayed Data
As of Dec 02
 -0.02 / -0.43%
Today’s Change
2.86
Today|||52-Week Range
9.98
-39.97%
Year-to-Date
Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA
Dec 02 / Zacks.com - Paid Partner Content
Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease
Nov 25 / Zacks.com - Paid Partner Content
Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA
Dec 02 / Zacks.com - Paid Partner Content
Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases
Nov 24 / Zacks.com - Paid Partner Content
Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer
Dec 01 / Zacks.com - Paid Partner Content
Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease
Nov 20 / Zacks.com - Paid Partner Content
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
Nov 27 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close4.60
Today’s open4.61
Day’s range4.56 - 4.70
Volume5,475
Average volume (3 months)45,452
Market cap$24.2M
Data as of 3:59pm ET, 12/02/2020

Growth & Valuation

Earnings growth (last year)+21.60%
Earnings growth (this year)+43.48%
Earnings growth (next 5 years)+21.00%
Revenue growth (last year)+14.85%
P/E ratioNM
Price/Sales0.67
Price/Book--

Competitors

 Today’s
change
Today’s
% change
CPHIChina Pharma Holding...+0.00+0.00%
ATHEAlterity Therapeutic...+0.04+2.86%
HOTHHoth Therapeutics In...+0.01+0.58%
TTNPTitan Pharmaceutical...-0.25-6.65%
Data as of 3:59pm ET, 12/02/2020

Financials

Next reporting dateMarch 3, 2021
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$53.9M
Annual profit (last year)-$10.4M
Net profit margin-19.36%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Alpharetta, Georgia

Forecasts